Depomed Inc. (NASDAQ:DEPO) shares were up 3% on Monday . The stock traded as high as $19.88 and last traded at $19.38, with a volume of 1,719,659 shares trading hands. The stock had previously closed at $18.81.

Several research analysts recently weighed in on DEPO shares. Royal Bank Of Canada reissued a “sector perform” rating and issued a $22.00 target price on shares of Depomed in a research note on Monday, May 2nd. Janney Montgomery Scott reissued a “buy” rating and issued a $28.00 target price on shares of Depomed in a research note on Wednesday, June 15th. Cantor Fitzgerald reissued a “buy” rating and issued a $26.00 target price on shares of Depomed in a research note on Tuesday, March 29th. Leerink Swann reissued a “positive” rating on shares of Depomed in a research note on Monday. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $23.00 target price on shares of Depomed in a research note on Thursday, March 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. Depomed presently has an average rating of “Buy” and an average target price of $22.89.

The stock has a 50 day moving average price of $19.65 and a 200 day moving average price of $17.08. The stock’s market capitalization is $1.18 billion.

Depomed (NASDAQ:DEPO) last announced its earnings results on Thursday, May 5th. The specialty pharmaceutical company reported $0.12 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.17 by $0.05. The company earned $104.60 million during the quarter, compared to analyst estimates of $106.88 million. The firm’s quarterly revenue was up 230.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.13) earnings per share. On average, equities analysts expect that Depomed Inc. will post $1.20 earnings per share for the current fiscal year.

In other news, CFO August J. Moretti sold 5,000 shares of the company’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $18.00, for a total transaction of $90,000.00. Following the completion of the sale, the chief financial officer now directly owns 22,879 shares of the company’s stock, valued at $411,822. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Thadd M. Vargas sold 15,000 shares of the company’s stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $17.64, for a total value of $264,600.00. Following the sale, the vice president now directly owns 124,297 shares of the company’s stock, valued at $2,192,599.08. The disclosure for this sale can be found here.

Several large investors recently made changes to their positions in the stock. US Bancorp DE increased its stake in shares of Depomed by 106.9% in the fourth quarter. US Bancorp DE now owns 55,393 shares of the specialty pharmaceutical company’s stock valued at $1,004,000 after buying an additional 28,622 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Depomed by 11.4% in the fourth quarter. ProShare Advisors LLC now owns 58,867 shares of the specialty pharmaceutical company’s stock valued at $1,067,000 after buying an additional 6,016 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Depomed by 11.2% in the fourth quarter. Rhumbline Advisers now owns 79,129 shares of the specialty pharmaceutical company’s stock valued at $1,435,000 after buying an additional 7,995 shares in the last quarter. California State Teachers Retirement System increased its stake in shares of Depomed by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 111,108 shares of the specialty pharmaceutical company’s stock valued at $2,014,000 after buying an additional 1,793 shares in the last quarter. Finally, Comerica Bank increased its stake in shares of Depomed by 4.6% in the fourth quarter. Comerica Bank now owns 111,771 shares of the specialty pharmaceutical company’s stock valued at $1,726,000 after buying an additional 4,957 shares in the last quarter.

Depomed, Inc is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company’s products include Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Gralise is a once-daily product for the management of postherpetic neuralgia (PHN).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.